R Squared Ltd Makes New $48,000 Investment in Voyager Therapeutics, Inc. $VYGR

R Squared Ltd acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 15,488 shares of the company’s stock, valued at approximately $48,000.

Several other large investors have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in shares of Voyager Therapeutics by 856.3% during the 1st quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after purchasing an additional 9,376 shares in the last quarter. Privium Fund Management B.V. acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth $73,000. Virtus Advisers LLC acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth $83,000. Ethic Inc. acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $123,000. Finally, Invesco Ltd. grew its holdings in shares of Voyager Therapeutics by 100.8% during the 1st quarter. Invesco Ltd. now owns 48,540 shares of the company’s stock worth $164,000 after purchasing an additional 24,368 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 2.2%

Voyager Therapeutics stock opened at $4.65 on Monday. The company has a market capitalization of $257.94 million, a PE ratio of -2.51 and a beta of 0.95. Voyager Therapeutics, Inc. has a 12 month low of $2.64 and a 12 month high of $7.44. The stock has a 50-day moving average price of $4.30 and a two-hundred day moving average price of $3.62.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. As a group, analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on VYGR shares. Wedbush reduced their target price on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.96.

Insider Buying and Selling

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.